Background:The relation between fibrosis biomarkers, suppressors or activators of fibrosis is incompletely studied in CHF of increasing severity.
Introduction
Increased collagen synthesis and degradation has been found in heart failure (1,2) and myocardial fibrosis is associated to development of Heart Failure (3, 4) . A number of studies performed in postmortem human hearts (5-7) and endomyocardial human biopsies have shown that fibrillar collagen deposition is increased in the myocardium of patients with left ventricular hypertrophy (8) (9) (10) (11) (12) . Furthermore, fibrosis is higher in more advanced stages of HF and is associated with a poor prognosis (13) (14) (15) (16) (17) . Serum concentrations of procollagen types (PIP) I and III can be considered as a useful markers of collagens type I and III synthesis (18) . Serum collagens I and III concentrations can represent their turnover levels (18) . A number of molecules may influence collagen turnover in HF of increasing severity.
TGFβ1 and its receptors R1 and R2 are involved in downregulation of inflammation (19, 20) , can regulate vascular morphogenesis and extracellular matrix synthesis (21) . A pro-angiogenic growth activity and increased cell survival stimulation has been reported for Stromal cell-derived factor-1α (SDF-1α) and its receptor CXCR4 (22, 23) .
Fibroblasts growth factors (FGF)1 and 2 (acidic and basic, respectively) are involved in the regulation of cardiac angiogenesis and repair (24) and FGF2 is required for development of cardiac hypertrophy (25) . Fibulins are involved in structural support, matrix-cell interactions and elastogenic activity (26) . Circulating Bone Morphogenic Proteins (BMP) 1-3 may have a pro-fibrotic effect in the kidneys (27) . BMP2 can suppresses renal interstitial fibrosis and TGFβ1 induced cardiac fibrosis (28, 29) . BMP4 reduced TGFβ1 induced extracellular matrix tenascin C and fibronectin production in cultured lung fibroblasts (30) . BMP4 inhibitor gremlin is over-expressed in idiopathic pulmonary fibrosis (31) . BMP7 suppresses hepatic fibrosis (32) , limits Smad3 DNA binding and decreases renal fibrosis (33) , reduces collagen content in asbestos treated mice (31) , preserves the endothelial cardiac phenotype avoiding the fibroblasts formation and fibrosis (34) . BMP endothelial cell precursor derived regulator (BMPER) interacts with BMPs and when overexpressed antagonizes their function (35) or regulates BMPs function (36) . Cysteine-rich motor neuron 1 (CRIM1) interacts with BMPs acting as an antagonist reducing production and processing of mature BMPs and decreasing secretion of BMPs (37, 38) . The BMP and activin membrane-bound inhibitor (BAMBI) is a membrane-spanning glycoprotein that acts as a negative regulator of TGFβ signaling (39) . A prevalent anti-fibrotic activity was postulated for the pseudoreceptor BAMBI that results up-regulated by TGFβ1 stimulation in the endothelium (40) .
Aim of the present study is to investigate serum/plasma biomarkers concentrations of fibrosis activators, fibrosis suppressors and regulators in patients with CHF of increasing severity and in a healthy control group of subjects and to evaluate possible correlations between fibrosis regulators and heart functional indexes.
Methods

Subjects
The total study population comprised 80 subjects. The CHF group was composed of 66 subjects with left ventricular dysfunction classified as follows: 9 in NYHA I, 34 in NYHA II and 23 in NYHA III. Characteristics of patients such as mean age, left ventricular ejection fraction (LVEF), sex, 6'WT, VO 2 max and etiology (ischemic (IHD) or idiopathic (ICM)) are summarized in tables 1 and 2. Table 2 shows a comparative analysis for age, LVEF%, 6'WT and VO2max between the IHD and ICM subgroups.
Patients receiving intravenous infusions, with severe valvular disease or with significant renal insufficiency were excluded from the study. The control group included 14 healthy volunteers matched for age and sex, without any documented history, signs or symptoms of heart failure, nor history of left ventricular dysfunction (table 1) . Clinical information, including demographics, co-morbidities, medications, and symptom level based on NYHA classification, were collected in the week before blood sample collection. At enrolment, all subjects underwent complete echocardiographic study. Left ventricular volumes were calculated from orthogonal apical views using the biplane area-length method, and ejection fraction was derived from the standard equation.
Deceleration time (DT) of early filling (ms) was measured, as a strong predictor of pulmonary capillary wedge pressure in patients with left ventricular dysfunction (41) , irrespective of the degree of mitral regurgitation (42) or atrial fibrillation (43) .
The study was carried out in conformity with the Declaration of Helsinki, and informed consent was obtained from each subject. This cross-sectional study was performed according to the local Ethics Committee Guidelines. Table 3 also shows the lower detection limits and the method of quantification (ELISA) for each of the molecules studied. Manufacturers' instructions were carefully followed for each of the ELISA kits used. Further details for each kit are available from the respective online datasheet.
Serum collection and analysis
Data analysis
Group data were expressed as mean  standard error for functional data or median (range or IQR) for serum/plasma levels data. Differences between groups were analysed using analysis of variance (ANOVA) for functional data. The Kruskal Wallis test was applied for serum/plasma levels data, followed -when differences were significant -by the Mann-Whitney U test for comparison between groups. Single regression analysis was performed using the Spearman correlation test. Probability values of p<0.05 were considered as significant. Data analysis was performed using the Stat View SE Graphics program (Abacus Concepts Inc., Berkeley, CA-USA).
Results
Subjects
Characteristics of the study population are summarized in Table 1 . Patients in NYHA class II and III were slightly older than NYHA I patients. Ischemic patients were slightly older (p=0.03) compared to idiopatic subjects and showed a significantly lower VO 2 max (p=0.01) (see table 2 for characteristics of patients when divided into ischemic and idiopathic subgroups).
Quantification of serum/plasma markers
Quantification of fibroblasts growth factor (FGF) basic and acidic and of Transforming
Growth Factor (TGF)β1 were not statistically different in the four groups of subjects studied, showing a low presence of these molecules both in patients and control subjects (table 4) . TGFβR1 was slightly decreased in NYHA class II (p=0.036) and III (p=0.020) compared to controls, even-though this difference was not revealed by Kruskal Wallis test for multiple comparisons. Interestingly, TGFβR2 increased significantly in NYHA class III compared to NYHA class II (p=0.011) and controls (p=0.018) (figure 1a). The TGFβ pseudo-receptor BAMBI was similarly expressed in all groups, showing a low expression in the four groups examined. The pro-angiogenic factor SDF1α was significantly increased in NYHA class III compared to NYHA class II (p=0.013), NYHA class I (p=0.014) and controls (p=0.0006) (figure 1b), at variance with its receptor CXCR4, which was similarly expressed in the four groups. Fibulins 1 and 2
were highly expressed in all subjects without any significant differences between groups. Fibulin 4 was significantly higher in NYHA class III patients compared to NYHA I (p=0.011), even though this difference was not confirmed by the more restrictive statistical analysis for multiple comparisons, the Kruskal Wallis test. Among the BMPs (BMP1, BMP2, BMP3, BMP7, BMP10) proteins analysed, BMP1 and BMP2
were the most abundantly expressed in all subjects without significant differences between groups. The BMP endothelial cell precursor derived regulator, BMPER is as well, modestly expressed, at a concentrations similar to BMP2, in all subjects without significant differences between groups. Interestingly, the BMPs antagonist CRIM1, was significantly higher in NYHA class III patients compared to NYHA class II (p=0.024), NYHA class I (p=0.011) and controls (p=0.054) (figure 1c). Collagen I and PIP I were similarly expressed in the four groups of patients studied. Collagen III was significantly higher in NYHA class III patients compared to controls (p=0.043). Most importantly, Procollagen (PIP) type III was significantly higher in NYHA class III patients compared to NYHA class II (p=0.0078), NYHA class I (p=0.047) and controls (p=0.0011) (figure 1d). NYHA class II patients also differed significantly from controls (p=0.038). These results are summarized in table 4.
When ischemic (IHD) were compared to idiopathic (ICM) patients, we did not observe any significant difference for all the molecules studied except for CRIM1 and Fibulin 4 serum concentrations which were reported as significantly higher in IHD compared to ICM patients. These results are summarized in table 5.
Correlations
In our patient cohort, none of the biomarkers studied correlated significantly with LVEF% at echocardiography. PIP III was inversely correlated with 6'WT (r=-0.37, The role of BMPs proteins as anti-fibrotic agents is sufficiently well documented in kidney (44) and liver (32) . Relatively few data are disposable in heart fibrosis. Recently, it was showed that in mice, pressure overload induced collagen deposition was decreased and cardiac function improved, after 2 weeks treatment with recombinant BMP-2 (29), suggesting a fibrosis antagonizing action for this molecule. In the serum of our CHF patients BMP-1,-2, -3, -7 and -10 were poorly represented being BMP-1 and BMP-2 the most expressed BMPs proteins. None of the BMPs proteins showed significant changes in CHF patients compared to controls, suggesting that their potential role as anti-fibrotic molecules could not be exerted in CHF patients of increasing severity. Since a number of molecules, such as BMP endothelial cell precursor derived regulator (BMPER) and cysteine-rich motor neuron 1 (CRIM-1) may have a regulatory or inhibitory role on BMPs proteins, we quantified these molecules in the serum of our CHF patients and controls. The BMPER serum levels were relatively low and similar in the four groups of patients studied, suggesting a minor role for this regulatory molecule.
Interestingly, we found significantly increased serum levels of CRIM-1 in NYHA class III CHF patients when compared to all the other groups studied and CRIM-1 serum levels were positively correlated with PIP III serum levels in CHF patients (figure 3). A negative significant correlation was also observed between CRIM-1 serum levels and 6'WT or DT(ms), showing, as an original contribution of the present study, a possible relationship between CRIM-1 levels and increased heart fibrosis, associated to a decreased ventilatory response and dynamic exercise performance of the patients ( figure   2 ). In "in vitro" experiments, CRIM-1 binding of BMP4 and -7 leads to a reduction in the production and secretion of mature BMPs (37) on metanephric explant cultures.
These data, together with our "in vivo" findings of an increased serum level of CRIM-1, associated to low serum levels of BMPs, invite to speculate on the possible BMPs inhibitory role of CRIM-1 and subsequent increased heart fibrosis, in our patients with CHF of increasing severity. Interestingly, in the sub-group of CHF patients with ischaemic hearth disease (IHD), CRIM-1 and also Fibulin-4, a molecule involved in the elastic fiber assembly, are significantly increased as compared to idiopathic cardiomyopathy (ICM) group. Also PIP III levels tended to be higher (p=0.11) in IHD compared to ICM patients (see table 5), suggesting again a pro-fibrotic role for these proteins in the more compromised patients with CHF.
The TGFβ pseudo-receptor BAMBI, for which a prevalent anti-fibrotic activity was reported (39, 45) , was similarly expressed in the four groups of subjects studied, suggesting a minor role for this protein in controlling the fibrotic changes developing in CHF of increasing severity.
A pro-angiogenic growth activity has been reported for SDF1α and its receptor CXCR4 (22, 23) . SDF1α was reported as increased in acute myocardial infarction (AMI) (22) , suggesting a contribution of bone marrow cells in myocardial regeneration (22) . In CHF patients, a three months physical training significantly increased serum levels of the pro-angiogenic markers angiopoietin-2 and CD34+ cells, but not of SDF1α, as compared with non-trained patients (46) . In contrast, a down-regulation of proangiogenic mechanisms, included SDF1α reduction, was reported in idiopathic pulmonary fibrosis (47) , suggesting that potentially differing mechanisms could be involved in cardiac and lung fibrosis. We here reported a significantly increased serum level of SDF1α in NYHA class III patients compared to all the other groups of subjects and a significant positive correlation between SDF1α and PIP III serum levels in patients with CHF of increasing severity ( figures 1 and 3) , suggesting a role for this proangiogenic molecule in heart remodelling. Since a parallel increase of its receptor CXCR4 was not observed in the plasma of our patients, the effective SDF1α biological activity developing in these patients needs to be more extensively elucidated by specifically designed "in vitro" studies.
Fibulins have a role in the assembly and stabilization of supramolecular extracellular matrix (ECM) complexes. They also can function as a modulators of cell growth, differentiation and angiogenesis (48) . Fibulin-1 and -2 interact with a wide number of ECM complexes, fibulin-4 interacts mainly with tropoelastin (48) . Fibulins-1 and -2 were the most expressed fibulins in the serum of our patients without significant differences between groups (table 4). Fibulin-4 was slightly increased in NYHA class III compared to NYHA class I patients, and it was correlated positively with PIP III serum levels (figure 3), probably as a consequence of the more direct relationship of this fibulin type with the cardiac function (48).
Molecules classically considered as fibrosis inductors, such as basic and acidic fibroblast growth factors and transforming growth factor(TGF)β1 were poorly recovered in the serum of our patients and controls (table 4) , showing no significant differences between groups. TGFβRI was slightly decreased in NYHA class II and III CHF patients, compared to controls. Interestingly, TGFβRII serum levels, increased significantly in NYHA class III compared to NYHA class II patients and controls (table   4) Table 4 Quantification of pro-fibrotic molecules and growth factors in the serum/plasma of patients with chronic heart failure and control subjects Tabella formattata
Tables
